potassium voltage-gated channel subfamily H member 6Genealiases: ERG-2 · ERG2 · HERG2 · Kv11.2 · hERG-2
Q-omics provides the consensus-scored KCNH6 profile across patient tissues and cancer cell-line models. KCNH6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNH6 is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, KCNH6 RNA expression shows 11,878 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where KCNH6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNH6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNH6 survival associations across molecular data types. KCNH6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNH6 RNA expression–survival associations across cancer types. High KCNH6 expression shows unfavorable associations in LUSC and UCS, but favorable associations in KIRC, PAAD, LGG and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNH6 RNA expression.
This table summarizes KCNH6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNH6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNH6 shows lower tumor expression in LUSC, KICH, KIRP and LUAD and higher tumor expression in BRCA and LIHC. The LUSC box plot shows higher KCNH6 RNA expression in normal versus tumor tissue (log2 FC = −0.789, t-test p < 0.001).
This table shows molecular features associated with KCNH6 in patient tissues and cancer cell lines. In patient samples, KCNH6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNH6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
